DE60113525D1 - Propansäure-derivate als integrin-rezeptor-antagonisten - Google Patents
Propansäure-derivate als integrin-rezeptor-antagonistenInfo
- Publication number
- DE60113525D1 DE60113525D1 DE60113525T DE60113525T DE60113525D1 DE 60113525 D1 DE60113525 D1 DE 60113525D1 DE 60113525 T DE60113525 T DE 60113525T DE 60113525 T DE60113525 T DE 60113525T DE 60113525 D1 DE60113525 D1 DE 60113525D1
- Authority
- DE
- Germany
- Prior art keywords
- acid derivatives
- receptor antagonists
- integrin receptor
- propanic acid
- propanic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0011817.4A GB0011817D0 (en) | 2000-05-16 | 2000-05-16 | Antagonists of integrin receptors |
GB0011817 | 2000-05-16 | ||
PCT/EP2001/004472 WO2001087840A1 (en) | 2000-05-16 | 2001-04-19 | Propanoic acid derivatives as integrin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60113525D1 true DE60113525D1 (de) | 2006-02-02 |
DE60113525T2 DE60113525T2 (de) | 2006-06-22 |
Family
ID=9891715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60113525T Expired - Fee Related DE60113525T2 (de) | 2000-05-16 | 2001-04-19 | Propansäure-derivate als integrin-rezeptor-antagonisten |
Country Status (10)
Country | Link |
---|---|
US (1) | US6974828B2 (de) |
EP (1) | EP1282602B1 (de) |
JP (1) | JP2003533511A (de) |
AR (1) | AR032327A1 (de) |
AT (1) | ATE305001T1 (de) |
AU (1) | AU6221201A (de) |
DE (1) | DE60113525T2 (de) |
ES (1) | ES2248333T3 (de) |
GB (1) | GB0011817D0 (de) |
WO (1) | WO2001087840A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1682537T3 (pl) | 2003-11-05 | 2012-09-28 | Sarcode Bioscience Inc | Modulatory adhezji komórkowej |
LT2444079T (lt) | 2005-05-17 | 2017-03-27 | Sarcode Bioscience Inc. | Kompozicijos ir būdai, skirti akių sutrikimų gydymui |
US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
EP2217238B1 (de) | 2007-11-08 | 2014-03-12 | The General Hospital Corporation | Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8783251B2 (en) * | 2010-02-12 | 2014-07-22 | Piper Medical, Inc | Enhanced manually actuated pressure controlled modulator technology |
EP3715345B8 (de) | 2012-07-25 | 2024-05-29 | Bausch + Lomb Ireland Limited | Herstellung eines lfa-1-hemmers |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
LT2953948T (lt) | 2013-02-07 | 2018-01-10 | Scifluor Life Sciences, Inc | Fluorinti integrino antagonistai |
RU2017132433A (ru) * | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997036862A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
DK0891325T3 (da) * | 1996-03-29 | 2002-05-21 | Searle & Co | Para-substituerede phenylpropansyrederivater som integrinantagonister |
PL190866B1 (pl) * | 1996-07-25 | 2006-02-28 | Biogen | Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
-
2000
- 2000-05-16 GB GBGB0011817.4A patent/GB0011817D0/en not_active Ceased
-
2001
- 2001-04-19 JP JP2001584236A patent/JP2003533511A/ja not_active Withdrawn
- 2001-04-19 ES ES01936253T patent/ES2248333T3/es not_active Expired - Lifetime
- 2001-04-19 WO PCT/EP2001/004472 patent/WO2001087840A1/en active IP Right Grant
- 2001-04-19 AU AU62212/01A patent/AU6221201A/en not_active Abandoned
- 2001-04-19 US US10/258,584 patent/US6974828B2/en not_active Expired - Fee Related
- 2001-04-19 AT AT01936253T patent/ATE305001T1/de not_active IP Right Cessation
- 2001-04-19 DE DE60113525T patent/DE60113525T2/de not_active Expired - Fee Related
- 2001-04-19 EP EP01936253A patent/EP1282602B1/de not_active Expired - Lifetime
- 2001-05-14 AR ARP010102270A patent/AR032327A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
DE60113525T2 (de) | 2006-06-22 |
US20030144311A1 (en) | 2003-07-31 |
ES2248333T3 (es) | 2006-03-16 |
AU6221201A (en) | 2001-11-26 |
EP1282602B1 (de) | 2005-09-21 |
JP2003533511A (ja) | 2003-11-11 |
GB0011817D0 (en) | 2000-07-05 |
AR032327A1 (es) | 2003-11-05 |
EP1282602A1 (de) | 2003-02-12 |
ATE305001T1 (de) | 2005-10-15 |
US6974828B2 (en) | 2005-12-13 |
WO2001087840A1 (en) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60120419D1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
DE60021370D1 (de) | Piperazinderivate verwendbar als ccr5 antagonisten | |
DE60023167T2 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
NO20032861D0 (no) | Heteroarylurea nevropeptid YY5-reseptorantagonister | |
ATE400558T1 (de) | Metabotropische glutamatrezeptor-antagonisten | |
ATE299866T1 (de) | Piperidinderivate verwendbar als ccr5 antagonisten | |
DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
ATE389648T1 (de) | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten | |
ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
ATE259363T1 (de) | Piperazinderivate als 5-ht1b antagonisten | |
ATE374191T1 (de) | Urea derivate als integrin alpha 4 antagonisten | |
DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
DE60118569D1 (de) | 4-phenylpyridin-derivate als neurokinin-1-rezeptor-antagonisten | |
ATE400554T1 (de) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten | |
DE60114852D1 (de) | Chinazolin-derivate als alpha-1 adrenerge antagonisten | |
DE60133931D1 (de) | Kondensierte purinderivate als a1-adenosinrezeptorantagonisten | |
DE60113525D1 (de) | Propansäure-derivate als integrin-rezeptor-antagonisten | |
ATE244716T1 (de) | Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten | |
NO20020644D0 (no) | Nye integrinreseptor-antagonister | |
DE60017110D1 (de) | Biphenylderivate als neurokinin-1 antagonisten | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
AU2002220598A1 (en) | Beta-amino acid derivatives as integrin receptor antagonists | |
NO20015237D0 (no) | Integrinreseptor-antagonister | |
NO20021113D0 (no) | Vitronectin-reseptor-antagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |